摘要
目的:系统评价痰热清注射液治疗小儿病毒性肺炎的临床疗效及安全性。方法:计算机检索中国知网、维普、万方、CBM数据库、中国临床试验注册中心、PubMed、the Cochorane Library、Embase、Clinical Trials,收集建库至2020年10月关于痰热清注射液治疗小儿病毒性肺炎的随机对照试验。使用RevMan 5.3软件进行统计分析。结果:共纳入16项研究,1 395例患儿。痰热清注射液治疗小儿病毒性肺炎的总有效率高于对照组,退热时间、咳嗽消失时间、喘息消失时间、肺部啰音消失时间短于对照组,不良反应发生率低于对照组且不良反应轻微。结论:痰热清注射液治疗小儿病毒性肺炎具有较好的临床疗效和安全性。
Objective: To systematically evaluate the clinical efficacy and safety of Tanreqing injection in the treatment of children with viral pneumonia. Methods: Chinese databases(CNKI, Wangfang, VIP, CBM, ChiCTR) and English databases(PubMed, the Cochrane Library, Embase and Clinical Trials) were searched by computer to collect randomized controlled trials on Tanreqing injection in the treatment of children with viral pneumonia from the establishment of the database to October 2020. The software RevMan 5.3 was used for Meta-analysis. Results: A total of 16 studies involving 1,395 children were included. The effective rate of Tanreqing injection in the treatment of children with viral pneumonia was higher than that of the control group, and the disappearance time of fever, cough, wheezing, rale, and the incidence of adverse reaction were lower than those of the control group, with mild adverse reactions. Conclusion: Tanreqing injection is effective and safe in the treatment of children with viral pneumonia.
作者
郑良栋
徐元翠
吴飞
覃鸿恩
徐先顺
杨丹
Zheng Liangdong;Xu Yuancui;Wu Fei;Qin Hongen;Xu Xianshun;Yang Dan(The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture,Hubei Enshi 445000,China)
出处
《儿科药学杂志》
CAS
2023年第2期39-43,共5页
Journal of Pediatric Pharmacy
